ReviewApplied microbiology and biotechnology2020
Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets.
Review in Applied microbiology and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.
- Infiltration to infection: key virulence players of Helicobacter pylori pathogenicity.Infection · 2024Pooled it
- Nanomechanical Hallmarks ofInternational journal of molecular sciences · 2021Trial
- High In Vitro Activity of the Novel Pleuromutilin Antibiotic, Lefamulin, on ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- Helicobacter pylori eradication in the face of escalating anti-microbial resistance: Geographic heterogeneity and emerging treatment strategies.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Review
- Effects of Helicobacter pylori infection on gastric mucosal microbiota.World journal of pediatrics : WJP · 2026Review
- Transcriptomic and Molecular Insights into the Response of Multidrug-Resistant Helicobacter pylori to Human Neutrophil Peptide 1 (HNP-1).Probiotics and antimicrobial proteins · 2026Article
- Potential mechanisms ofFrontiers in microbiology · 2026Review
- The association between red blood cell distribution width-to-albumin ratio andFrontiers in nutrition · 2026Article
- Structure-guided identification of a potential inhibitor targeting the VacA toxin of Helicobacter pylori.PloS one · 2026Article
- Bicarinalin Enhances the Antibacterial Activity of Levofloxacin and Clarithromycin AgainstAntibiotics (Basel, Switzerland) · 2025Article
- Effects of Lactobacillus spp. on Helicobacter pylori: A Promising Frontier in the Era of Antibiotic Resistance.Probiotics and antimicrobial proteins · 2025Review
- Novel chromogenic medium-based method for the rapid detection ofWorld journal of gastroenterology · 2025Article
- Anti-Molecules (Basel, Switzerland) · 2025Article
- Design, synthesis, and anti-urease evaluations of new sulfonamide-1,2,3-triazole-acetamide derivatives.Scientific reports · 2025Article
- Peculiarities of Diagnostic Reliability-Nested PCR Versus SAT in the Identification ofMicroorganisms · 2025Article
- New Quipazine Derivatives Active Against Drug-Resistant OncogenicInternational journal of molecular sciences · 2025Article
- Challenges and Prospects for Eradication ofPathogens (Basel, Switzerland) · 2025Review
- Pilot study on seasonal variability in microbial contamination in the developing tourist region of Mindo, Ecuador: a comparative analysis of the Saguambi, Mindo, and Canchupí Rivers.BMC research notes · 2025Article
- Prevalence and Variability ofAntibiotics (Basel, Switzerland) · 2025Article
- D-Glucosamine is a Potential Urease Inhibitor from Middle Eastern Medicinal Plants for Combatting Helicobacter Pylori Infections; a Molecular Docking and Simulation Approach.Biochemical genetics · 2025Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Helicobacter pylori, a member of Epsilonproteobacteria, is a Gram-negative microaerophilic bacterium that colonizes gastric mucosa of about 50% of the human population. Although most infections caused by H. pylori are asymptomatic, the microorganism is strongly associated with serious diseases of the upper gastrointestinal tract such as chronic gastritis, peptic ulcer, duodenal ulcer, and gastric cancer, and it is classified as a group I carcinogen. The prevalence of H. pylori infections varies worldwide. The H. pylori genotype, host gene polymorphisms, and environmental factors determine the type of induced disease. Currently, the most common therapy to treat H. pylori is the first line clarithromycin-based triple therapy or a quadruple therapy replacing clarithromycin with new antibiotics. Despite the enormous recent effort to introduce new therapeutic regimens to combat this pathogen, treatment for H. pylori still fails in more than 20% of patients, mainly due to the increased prevalence of antibiotic resistant strains. In this review we present recent progress aimed at designing new anti-H. pylori strategies to combat this pathogen. Some novel therapeutic regimens will potentially be used as an extra constituent of antibiotic therapy, and others may replace current antibiotic treatments. KEY POINTS: • Attempts to improve eradication rate of H. pylori infection. • Searching for new drug targets in anti-Helicobacter therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.